{"filing":{"accession_number":"0001753926-26-001349","cik":"0001266806","ticker":"VANI","company_name":"Vivani Medical, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"vani-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1266806/000175392626001349/vani-20260806.htm"},"events":[{"id":25962,"run_id":23576,"accession_number":"0001753926-26-001349","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Vivani Medical announced successful completion of enrollment and dosing of all 20 participants in the SLIM-1 Phase 1 clinical trial for NPM-139, a semaglutide implant candidate. This is a material clinical development milestone—full enrollment ahead of schedule and successful dosing of all participants—that advances the company's product pipeline and supports the anticipated Phase 2 initiation in 2027. While not a specific named event type, this is clearly an operational/strategic milestone in drug development that would affect a reasonable investor's assessment of the company's progress and prospects.","company_name":"Vivani Medical, Inc.","ticker":"VANI","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26915,"accession_number":"0001753926-26-001349","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Vivani Medical announced successful completion of enrollment and dosing of all 20 participants in the SLIM-1 Phase 1 clinical trial for NPM-139, a semaglutide implant candidate. This is a material clinical development milestone—full enrollment ahead of schedule and successful dosing of all participants—that advances the company's product pipeline and supports the anticipated Phase 2 initiation in 2027. While not a specific named event type, this is clearly an operational/strategic milestone in drug development that would affect a reasonable investor's assessment of the company's progress and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:50:28.870060+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26915,"accession_number":"0001753926-26-001349","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Vivani Medical announced successful completion of enrollment and dosing of all 20 participants in the SLIM-1 Phase 1 clinical trial for NPM-139, a semaglutide implant candidate. This is a material clinical development milestone—full enrollment ahead of schedule and successful dosing of all participants—that advances the company's product pipeline and supports the anticipated Phase 2 initiation in 2027. While not a specific named event type, this is clearly an operational/strategic milestone in drug development that would affect a reasonable investor's assessment of the company's progress and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:50:28.870060+00:00","company_name":"Vivani Medical, Inc.","ticker":"VANI","filing_date":"2026-08-06"}]}